CXC motif ligand 12 as a novel diagnostic marker for papillary thyroid carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chung, Soo Young | - |
dc.contributor.author | Park, Eon Sub | - |
dc.contributor.author | Park, So Yeon | - |
dc.contributor.author | Song, Joo-Yeon | - |
dc.contributor.author | Ryu, Han Suk | - |
dc.date.available | 2019-03-08T21:40:27Z | - |
dc.date.issued | 2014-07 | - |
dc.identifier.issn | 1043-3074 | - |
dc.identifier.issn | 1097-0347 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/12066 | - |
dc.description.abstract | Background. We subjected chemokine (C-X-C motif) ligand 12 (CXCL12) to immunohistochemistry to determine its utility as a novel diagnostic marker for papillary thyroid carcinoma (PTC) in comparison to cytokeratin 19 (CK19), Hector Battifora mesothelial epitope-1 (HBME-1), and galectin-3. Methods. We analyzed the expressions of CXCL12, CK19, HBME-1, and galectin-3 using immunohistochemical staining in 258 cases of thyroid lesions (196 PTCs and 62 thyroid lesions excluding PTC). Results. Remarkably, CXCL12 expression was exclusively found in PTC compared to other thyroid lesions (90.8% vs 3.2%; p < .001). In total, 91.1% (62 of 68) of the variant PTCs and 90.6% of conventional type (116 of 128) were associated with CXCL12 immunohistochemical expression, irrespective of the histological subtype. In contrast, very few of the thyroid lesions, excluding PTC, were positive for CXCL12 (2 of 62; 3.2%). Diagnostic performances for PTCs were as follows: sensitivity, 90.8%; specificity, 96.8%; positive predictive value, 98.9%; negative predictive value, 76.9%; and diagnostic accuracy, 92.2%. Conclusion. Our findings indicate that CXCL12 might serve as an effective novel supplementary diagnostic marker for PTC. (C) 2013 Wiley Periodicals, Inc. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | WILEY | - |
dc.title | CXC motif ligand 12 as a novel diagnostic marker for papillary thyroid carcinoma | - |
dc.type | Article | - |
dc.identifier.doi | 10.1002/hed.23404 | - |
dc.identifier.bibliographicCitation | HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, v.36, no.7, pp 1005 - 1012 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000337618800015 | - |
dc.identifier.scopusid | 2-s2.0-84902543657 | - |
dc.citation.endPage | 1012 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 1005 | - |
dc.citation.title | HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | - |
dc.citation.volume | 36 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | papillary thyroid carcinoma | - |
dc.subject.keywordAuthor | CXCL12 | - |
dc.subject.keywordAuthor | immunohistochemistry | - |
dc.subject.keywordAuthor | diagnostic marker | - |
dc.subject.keywordPlus | MOLECULAR-WEIGHT CYTOKERATIN | - |
dc.subject.keywordPlus | DIFFERENTIAL-DIAGNOSIS | - |
dc.subject.keywordPlus | IMMUNOHISTOCHEMICAL MARKERS | - |
dc.subject.keywordPlus | GALECTIN-3 | - |
dc.subject.keywordPlus | HBME-1 | - |
dc.subject.keywordPlus | TUMORS | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | UTILITY | - |
dc.subject.keywordPlus | LESIONS | - |
dc.subject.keywordPlus | BENIGN | - |
dc.relation.journalResearchArea | Otorhinolaryngology | - |
dc.relation.journalResearchArea | Surgery | - |
dc.relation.journalWebOfScienceCategory | Otorhinolaryngology | - |
dc.relation.journalWebOfScienceCategory | Surgery | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.